Sunday 18 October 2026
Export NXL’s income statement to Excel — free account
Nexalin Technology, Inc.
NXL Healthcare Medical Devices
Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024. In the quarter to June 2026, revenue fell 82.7%, EPS fell 10.0% and free cash flow fell 97.2%, each against the same quarter a year earlier.
2.35
0.10
−4.08%
Follow NXL
Nexalin Technology, Inc. (NXL) P/E ratio
Nexalin Technology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NXL Nexalin Technology, Inc. | n/m |
| XAIR Beyond Air, Inc. compare | n/m |
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| ADGM Adagio Medical Holdings, Inc. compare | n/m |
| NUWE Nuwellis, Inc. compare | n/m |
| VJET Flyte Aviation, Inc. compare | n/m |
| BIOLQ Biolase, Inc. compare | n/m |
| IVF INVO Fertility, Inc compare | 0.0× |
| BJDX Bluejay Diagnostics, Inc. compare | 0.9× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)